Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company, announced on April 3, 2023, that its Board of Directors granted stock options and restricted stock units (RSUs) to 10 new employees. The awards consist of stock options for 77,550 shares and RSUs for 132,925 shares, incentivizing new talent joining the company in March 2023. The stock options have an exercise price of $4.25 per share, matching the closing price on the grant date. These options will vest over four years, starting with 25% on the one-year employment anniversary. RSUs will vest annually over four years. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance employee retention and growth as Mersana continues its focus on developing novel antibody-drug conjugates targeting cancer.

Positive

• Granting of stock options and RSUs to attract new talent supports growth.
• Stock options priced at $4.25 align with market value, potentially incentivizing employees.

Negative

• None.

CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 77,550 shares of its common stock and restricted stock unit awards (RSUs) to acquire an aggregate of 132,925 shares of its common stock, to 10 new employees whose employment commenced in March 2023. The awards were granted pursuant to terms and conditions fixed by the Compensation Committee and as an inducement material to each new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).

The option awards have an exercise price of $4.25 per share, which is equal to the closing price of Mersana’s common stock on April 3, 2023. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the commencement of the employee’s employment and the remainder vesting in equal quarterly installments over the following three years, subject to the applicable employee’s continued service with Mersana on each such vesting date. The options are subject to the terms and conditions of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and conditions of a stock option agreement covering each grant.

The RSUs will vest in equal annual installments on the first four anniversaries of February 15, 2023, subject to the applicable employee’s continued service with Mersana on each such vesting date. The RSUs are subject to the terms and conditions of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and conditions of an RSU agreement covering each grant.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi in combination with carboplatin; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase 1 clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

What is the recent stock option grant by Mersana Therapeutics (MRSN)?

Mersana granted stock options for 77,550 shares and RSUs for 132,925 shares to 10 new employees as part of employee incentives.

What is the exercise price for Mersana's stock options granted in April 2023?

The exercise price for the stock options is $4.25 per share, equal to the closing price on the grant date.

When will the stock options granted by Mersana Therapeutics vest?

The stock options will vest over four years, with 25% vesting on the one-year anniversary of employment.